PE-related deaths among patients with cancer increased 44.3% between 2011 and 2020, rising by about 2.9% each year during the study period ( P <.001). On average, the age-adjusted mortality rate (AAMR ...

Inpatient immune checkpoint inhibitor treatment produces poor outcomes across cancer types, according to the largest study of its kind.

The FDA has granted priority review to the new drug application for zongertinib to treat adults with unresectable or metastatic, HER2-mutant NSCLC who have received prior systemic therapy.